Experimental evidence of interleukin-2 activity in bone marrow transplantation

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Mazumder, Amitabha ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Bone marrow transplantation; Graft versus tumor effect; Graft versus host disease; Interleukin 2; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; RECOMBINANT PROTEINS;

EID: 0031416081     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
2. Malkovsky M, Brenner MK, Hunt R et al. T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol 1986;103:476-480.
3. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991;77:211-213.
4. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-1176.
5. Pavletic Z, Benyunes MC, Thompson JA et al. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. Exp Hematol 1993;21:1371-1378.
6. Chadwick BS, Miller RG. Heterogeneity of the lymphokine-activated killer cell phenotype. Cell Immunol 1991;132:168-176.
7. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatmenr of 652 cancer patients. Ann Surg 1989;210:474-485.
8. Charak BS, Brynes RK, Katsuda S et al. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy. Cancer Res 1991;51:2015-2020.
9. Charak BS, Agah R, Gray D et al. Interaction of various cytokines with interleukin-2 in the generation of killer cells from human bone marrow: application in purging of leukemia. Leuk Res 1991;15:801-810.
10. Gilboa E, Lyerly HK, Vieweg J et al. Immunotherapy of cancer using cyrokine gene-modified tumor vaccines. Semin Cancer Biol 1994;5:409-417.
11. Guadagni F, Roselli M, Schlom J et al. In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: a review. Int J Biol Markers 1994; 9:53-60.
12. Agah R, Malloy B, Kemer M et al. Generation and characterization of IL-2 activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol 1989;143:3093-3099.
13. Champlin R. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation. Semin Hematol 1992;29:46-52.
14. Champlin R. T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother 1993;2:27-42.
15. Champlin R. Immunobiology of bone marrow transplantation as treatment for hematologic malignancies. Transplant Proc 1991;23:2123-2127.
16. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992;79: 517-526.
17. Glazier AD, Tutschka PJ, Farmer ER et al. Graft-versus-host disease in cyclosporine A-treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1983;158: 1-8.
18. Hess AD, Jones RC, Santos GW. Autologous graft-versus-host disease: mechanism and potential therapeutic effect. Bone Marrow Transplant 1993;12[suppl 3]:S65-S69.
19. Sykes M, Harty MW, Szot GL et al. Interleukin-2 inhibits graft versus host-disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994;83:2560-2569.
20. Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994;12:249-257.
21. Heslop HE, Gottlieb DJ, Bianchi ACM et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous bone marrow transplantation. Blood 1989;74:1374-1380.
22. Fefer A, Benyunes M, Higuchi C et al. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 1993;89[suppl 1]:2-7.
23. Bosly AE, Staquet PJ, Doyen CM et al. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. Exp Hematol 1987;15:1048-1054.
24. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin 2: half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant rIL-2. J Immunol 1985;135:2865-2875.
25. Areman EM, Mazumder A, Kotula P et al. Hematopoietic potential of IL-2 cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant 1996;18:521-525.
26. Massumoto C, Sale G, Benyunes M et al. Cutaneous GVHD associated with rIL-2 + LAK therapy after autologous bone marrow transplantation (ABMT) for hematologic malignancies [abstract]. Proceedings of ASCO 1992;11:254.
27. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990;76:1092-1097.
28. Favrot MC, Floret D, Negrier S et al. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1989;4:499-503.
29. Keever CA, Pekle K, Gazzola MV et al. NK and LAK activities from human bone marrow progenitors. I. The effects of interleukin-2 and interleukin-1. Cell Immunol 1990;126:211-226.
30. Gottlieb DJ, Brenner MK, Heslop HE et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989;60: 610-615.
31. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561-2568.
32. Soiffer Rf, Murray C, Gonin R et al. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994;84:964-971.
33. Weisdorf DJ, Anderson PM, Blazar BR et al. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia: a phase I study. Transplantation 1993;55:61-66.
34. Charak BS, Byrnes RK, Groshen S et al. Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990;76:2187-2190.
35. Benyunes MC, Massumoto C, York A et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993;12:159-163.
36. Verma UN, Bagg A, Brown E et al. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 1994;13:115-123.
37. Charak BS, Malloy B, Agah R et al. A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplant 1990;6:193-198.
38. Agah R, Malloy B, Kerner M et al. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin-2-activated syngeneic bone marrow in mice. Cancer Res 1989;49:5959-5963.
39. Klingemann HG, Deal H, Reid D et al. Preclinical evaluation of a bone marrow autograft culture procedure for generating lymphokine-activated killer cells in vitro. Can J Infect Dis 1992;3:123B-127B.
40. Verma UN, Areman E, Dickerson SA et al. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 1995;15:199-206.
41. Meehan KR, Verma UN, Rajagopal C et al. Stem cell transplantation with high dose chemoradiotherapy myeloblation and interleukin-2. J Infus Chemother 1995;6:28-32.
42. Meehan KR, Verma UN, Rajagopal C et al. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer: clinical and biological correlates. Bone Marrow Transplant; in press.